SEARCH

SEARCH BY CITATION

References

  • 1
    Glantz MJ,Jaeckle KA,Chamberlain MC, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res. 1999; 5: 3394-3402.
  • 2
    Chamberlain MC,Kormanik, PA. Prognostic significance of 111Indium- DTPA CSF flow studies in leptomeningeal metastases. Neurology. 1996; 46: 1674-1677.
  • 3
    Chamberlain MC,Dirr L. Involved field radiotherapy and intra-Ommaya methotrexate/ara-C in patients with AIDS-related lymphomatous meningitis. J Clin Oncol. 1993; 11: 1978-1993.
  • 4
    Freilich RJ,Krol G,DeAngelis LM. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol. 1995; 38: 51-57.
  • 5
    Log Rank Test (2xK tables). In: Miller RGJr, ed. Survival Analysis. New York: John Wiley & Sons; 1981: 114-118.
  • 6
    SAS Institute Inc. SAS Version 8. Cary, NC: SAS Institute Inc; 1999.
  • 7
    Epicenter Software. Epilog Window: Epicenter Software. Pasadena, Calif: Epicenter Software; 1999.
  • 8
    Chamberlain MC,Kormanik P. Prognostic significance of co-existent bulky metastatic central nervous system disease in patients with leptomeningeal metastases. Arch Neurol. 1997; 54: 1364-1368.
  • 9
    Glantz M,Jaeckle KA,Chamberlain MC, et al. A randomized trial of a slow-release formulation of cytarabine for the treatment of lymphomatous meningitis. J Clin Oncol. 1999; 17: 3110-3116.
  • 10
    Mason WP,Yeh SD,DeAngelis LM. 111Indium-diethylenetriamine pentaacetic acid CSF flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases. Neurology. 1998; 50: 438-448.
  • 11
    Sherman AM,Jaeckle K,Meyers CA. Pretreatment cognitive performance predicts survival in patients with leptomeningeal disease. Cancer. 2002; 95: 1311-1316.
  • 12
    Glantz MJ,Chamberlain MC,Walters BC. Diagnosis and outcome measures in trials for neoplastic meningitis: a review of the literature and clinical experience. Neurosurg Focus. 1998; 4: 1-7.
  • 13
    Grossman SA,Finkelstein DM,Ruckdeschel JC, et al. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. J Clin Oncol. 1993; 11: 561-569.
  • 14
    Hitchins RN,Bell DR,Woods RL, et al. A prospective randomized trial of single agent, versis combination chemotherapy in meningeal carcinomatosis. J Clin Oncol. 1987; 5: 1655-1662.
  • 15
    Glantz MJ,Hall WA,Cole BF, et al. Diagnosis, management, and survival of patients with lemptomeningeal cancer based on CSF flow studies. Cancer. 1995; 75: 2919-2931.
  • 16
    Chamberlain MC,Tsao-Wei D. Neoplastic meningitis-related encephalopathy: prognostic significance. Neurology. 2005; 63: 2159-2161.
  • 17
    Brem SS,Bierman PJ,Black P, et al. Central nervous system cancers: clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2005; 3: 644-690.
  • 18
    Glass JP,Melamed M,Chernik NL, et al. Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology. 1979; 29: 1369-1375.
  • 19
    Boyle R,Thomas M,Adams JH. Diffuse involvement of the leptomeninges by tumour-a clinical and pathological study of 63 cases. Postgrad Med J. 1980; 56: 149-158.
  • 20
    Chamberlain MC. Cytologically negative carcinomatous meningitis: usefulness of CSF biochemical markers. Neurology. 1993; 50: 1173-1175.